Author:
Gutzmer Ralf,Harrington Kevin J.,Hoeller Christoph,Lebbé Celeste,Malvehy Josep,Öhrling Katarina,Downey Gerald,Dummer Reinhard
Reference65 articles.
1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658–70.
2. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14: 559–67.
3. Amgen Europe B.V. IMLYGIC® (talimogene laherparepvec). Summary of product characteristics. 2016. Available at: https://doi.org/www.medicines.org.uk/emc/medicine/31351.
4. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292–303.
5. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laher-parepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780–8.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献